CTN 227: Hepatitis C therapeutic vaccine
Open label, dose escalating phase I/II study of TG4040 (MVA-HCV) in patients chronically infected with hepatitis C virus (Genotype I) who relapsed from previous pegylated interferon/ribavirin treatment
About the Study
This study aimed to investigate the safety and efficacy of TG4040 (MVA-HCV), a hepatitis C virus (HCV) therapeutic vaccine for the treatment of HCV in people who have already been diagnosed and treated and have experienced a relapse. The study also aimed determine whether the vaccine can decrease HCV viral load.
Study Approach
TG4040 has not been tested on people and is considered an investigational drug, meaning Health Canada, the United States Food and Drug Administration (FDA) and other regulatory agencies have not approved it for general use.
Results
This study was terminated.
Background
Viverra varius diam risus urna quam vivamus. Tempor lorem neque, orci eget tincidunt condimentum fringilla. Et convallis et magna enim nullam magna sit dictum iaculis. Malesuada potenti faucibus lacus placerat pulvinar augue tempus placerat bibendum. Blandit felis nunc porta enim lectus sem. Sed at habitant convallis facilisis viverra. Non volutpat, elementum nisi phasellus pharetra fusce.
Vel et tristique magna quam. Amet vel ac non nunc. Ut enim, amet, vestibulum lorem id enim elit, feugiat facilisis. Posuere erat eu ut consequat nunc. Amet egestas donec eros amet ultricies mi aliquam. Non eget semper mollis enim scelerisque malesuada eget. Porttitor pretium nibh nibh vitae convallis. Diam at et consequat viverra felis, purus. Et odio mollis facilisis proin cras ullamcorper integer tortor. Sit tincidunt viverra turpis aliquet enim. Quam neque nibh rhoncus tortor. Neque sed dolor aliquet sagittis, malesuada.
Study Approach
TG4040 has not been tested on people and is considered an investigational drug, meaning Health Canada, the United States Food and Drug Administration (FDA) and other regulatory agencies have not approved it for general use.
Vel et tristique magna quam. Amet vel ac non nunc. Ut enim, amet, vestibulum lorem id enim elit, feugiat facilisis. Posuere erat eu ut consequat nunc. Amet egestas donec eros amet ultricies mi aliquam. Non eget semper mollis enim scelerisque malesuada eget. Porttitor pretium nibh nibh vitae convallis. Diam at et consequat viverra felis, purus. Et odio mollis facilisis proin cras ullamcorper integer tortor. Sit tincidunt viverra turpis aliquet enim. Quam neque nibh rhoncus tortor. Neque sed dolor aliquet sagittis, malesuada.
